![]() |
|
|
Vol. 62, Issue 2, 398-405, August 2002
The University of Pittsburgh School of Medicine, Division of Infectious Diseases, Pittsburgh, Pennsylvania
| |
Abstract |
|---|
|
|
|---|
N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde
hydrazone (BBNH) inhibits both the DNA polymerase and ribonuclease H
(RNase H) activities of the human immunodeficiency virus type 1 reverse transcriptase. In this study, we show that BBNH binding impacts on the
stability of the human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) heterodimer. The Gibbs free energy of dimer
dissociation of HIV-1 RT is decreased in the presence of
increasing concentrations of BBNH, resulting in a loss in stability of
3.8 kcal mol
1. To evaluate whether this observed
phenomenon was mediated by BBNH binding to one or more sites in RT, we
synthesized a variety of BBNH analogs and identified
(4-t-butylbenzoyl)-2-hydroxy-1-salicylyl hydrazone
(BBSH) and
(4,N,N-dimethylaminobenzoyl)-2-hydroxy-1-naphthyl hydrazone as specific inhibitors of RT DNA polymerase or RT RNase H
activity, respectively. Interestingly, only BBSH provided significant destabilization of the HIV-1 RT dimer. The identification of these specific inhibitors, in combination with other biochemical data, suggests a model in which two molecules of BBNH bind per RT
heterodimer. In this regard, only the binding of hydrazone molecules in
the DNA polymerase domain activity elicits the observed destabilization of the HIV-1 RT heterodimer.
| |
Introduction |
|---|
|
|
|---|
The
multifunctional human immunodeficiency virus (HIV) type 1 reverse
transcriptase (RT) catalyzes the conversion of single-stranded viral
genomic RNA into double-stranded DNA. HIV-1 RT has RNA-dependent DNA
polymerase activity (RDDP) to synthesize a (
)-strand DNA copy of the
(+)-genomic RNA, RNase H activity to digest the RNA component of the
resultant (+)RNA/(
)DNA duplex, and DNA-dependent DNA polymerase
activity to synthesize (+)DNA using the (
)DNA as template.
Numerous inhibitors of HIV-1 RT have been identified, 10 of which are
in current clinical use as treatment for HIV infection (see
Sluis-Cremer et al., 2000a
and Parniak and Sluis-Cremer, 2000
for
recent reviews). However, the majority of these inhibitors are directed
at the DNA polymerase activity of RT, and they all function primarily
at preintegrational stages of virus replication. Unfortunately, HIV-1
readily develops resistance to these inhibitors, and therefore, the
identification of other compounds that exhibit novel mechanisms of
action is essential.
The gene for HIV-1 RT encodes a 66-kDa polypeptide; however, the
biologically relevant form of the enzyme is considered to be a
heterodimer consisting of two subunits of 66 and 51 kDa. The latter
subunit is derived from the former by proteolytic processing during
HIV-1 assembly and maturation. Although the precise kinetics of HIV-1
RT processing and dimerization are not well characterized, it is clear
that the expression of RNA-dependent DNA polymerase and RNase H
activities requires a dimeric enzyme (Restle et al., 1990
, 1992
; Divita
et al., 1995a
,b
). Therefore, inhibition of RT dimerization or the
disruption of RT dimer stability could provide alternative targets for
HIV-1 inhibition (Divita et al., 1994
; Morris et al., 1999a
,b
;
Sluis-Cremer et al., 2000b
). In regard to the latter strategy of RT
inhibition, we have recently shown that
1-{spiro[4-amino-2,2-dioxo-1,2-oxathiole-5,3'-[2',5'-bis-O-(tert-butyldimethylsilyl)-
-D-ribofuranosyl]]}-3-ethylthymine (TSAOe3T) destabilizes the subunit interactions
of both p66/p51 heterodimer and p66/p66 homodimer forms of HIV-1 RT
(Sluis-Cremer et al., 2000b
).
We previously identified
N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde
hydrazone (BBNH; Fig. 1, compound
1) as a multitarget inhibitor of HIV-1 RT, active against both
the DNA polymerase and RNase H activities of the enzyme (Borkow et al.,
1997
). We have proposed that BBNH exerts its multitarget inhibition by
binding to two spatially separate sites in RT, one in the DNA
polymerase domain and the other in the RNase H domain (Borkow et al.,
1997
; Arion et al., 2002
). Furthermore, we have shown that treatment of
HIV-1 chronically infected H9 cells with an appropriately formulated iron chelate of BBNH [Fe(III)BBNH as SP1093V] resulted in a nascent virus that was significantly attenuated in infectivity, thus suggesting a postintegrational target for this inhibitor. However, viral p24
levels and HIV-1 protein processing in the nascent virions were
unaffected by Fe(III)BBNH (Parniak et al., 1998
). Although this
compound targets RT, its enzymatic activities are not necessary for the
postintegrational stages of HIV replication. Because RT is an
obligatory dimer, we considered that BBNH might act at the level of RT
dimer stability.
|
Our results indicate that BBNH considerably decreases the dimeric stability of p66/p51 HIV-1 RT. To determine whether BBNH binding to both the DNA polymerase and RNase H domains in RT was an important criterion for dimer destabilization, we synthesized a variety of BBNH analogs and identified (4-t-butylbenzoyl)-2-hydroxy-1-salicylyl hydrazone (BBSH), which binds specifically to the polymerase domain, and (4,N,N-dimethylaminobenzoyl)-2-hydroxy-1-naphthyl hydrazone (DABNH), which binds only to the RNase H domain. The structures of BBNH, BBSH, and DABNH are illustrated in Fig. 1. Only BBNH and BBSH provided significant destabilization of the HIV-1 RT dimer, suggesting that the interaction with a site in the RT DNA polymerase domain is important for the dimer-destabilizing activity of the compound.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Recombinant HIV-1 RT p66/p51 heterodimer was
expressed and purified essentially as described previously (Fletcher et
al., 1996
). [3H]dNTPs,
-[32P]ATP, and the homopolymeric
template/primers (T/P) poly(rA)-oligo(dG)12-18 and poly(rC)-oligo(dG)12-18 were products of
Amersham Biosciences (Montreal, QC, Canada). Heteropolymeric T/P
was prepared using an RNA transcript derived from pHIV-PBS and a
synthetic 18-mer oligonucleotide primer (Arts et al., 1994
). The RNase
H substrate poly([3H]rG)-poly(dC) was
prepared as described previously (Starnes and Cheng, 1989
). Nevirapine
was obtained from Boehringer-Ingelheim (Canada) Ltd. (Laval, QC,
Canada). BBNH and derivatives thereof were synthesized by standard
methods (Edward et al., 1988
). All other reagents were of the highest
quality available and were used without further purification.
Assay of RT DNA Polymerase Activity. HIV-1 RT DNA polymerase activity was determined by a fixed time assay. Reaction mixtures (50 µl total volume) contained 50 mM Tris-HCl (pH 7.8, 37°C), 60 mM KCl, 10 mM MgCl2, 5 µg/ml of either poly(rA)-oligo(dT)12-18 or poly(rC)-oligo(dG)12-18, and either 20 µM [3H]TTP or 10 µM [3H]dGTP. Reactions were initiated by the addition of 50 to 80 ng of RT (9-12 nM final concentration). Reaction mixtures were incubated at 37°C for 20 min and then quenched with 250 µl of ice-cold 10% trichloroacetic acid containing 20 mM sodium pyrophosphate. Quenched samples were left on ice for 20 min then filtered using 1.2-µm glass fiber Type C filter multiwell plates (Millipore Corp., Bedford, MA) and washed sequentially with 10% trichloroacetic acid containing 20 mM sodium pyrophosphate and with 100% ethanol. The extent of radionucleotide incorporation was determined by liquid scintillation spectrometry of the dried filters.
Assay of RT RNase H Activity. RT RNase H activity was assayed using either the homopolymeric poly([3H]rG)-poly(dC) substrate or a 5'-32P-labeled heteropolymeric RNA template (5'-GAUCUGAGCCUGGGAGCU-3') annealed to a complementary DNA oligonucleotide (3'-CTAGACTCGGACCCTCGA-5'). Assays of RT RNase H activity using the homopolymeric substrate were carried out in reaction mixtures (50 µl total volume) that contained 50 mM Tris-HCl (pH 8.0, 37°C), 60 mM KCl, 10 mM MgCl2, and 2 µg/ml poly([3H]rG)-poly(dC). Reactions were initiated by the addition of RT (generally, 50 ng of p66/p51 RT, to provide a 9 nM final concentration), followed by 20 min incubation at 37°C. Reactions were quenched by placing the tubes on ice followed by the addition of 100 µl of cold 7% perchloric acid. After 30 min on ice, the reaction mixtures were centrifuged at 12000g for 15 min. The supernatants (100 µl) were carefully removed, and the radioactivity was determined by liquid scintillation analysis.
RT RNase H assays using the heteropolymeric RNA/DNA hybrid duplex were carried out in 10-µl aliquots, which included 50 mM Tris-HCl (pH 8.0, 37°C), 60 mM KCl, 10 mM MgCl2, 7.5 pmol of DNA antisense oligonucleotide, and 2.5 pmol of 32-P 5'end-labeled RNA. Reactions were initiated by the addition of RT (10 nM final concentration), incubated for 15 min (37°C), and then quenched by adding sequencing loading dye buffer (98% deionized formamide, 10 mM EDTA, 1 mg/ml bromphenol blue, and 1 mg/ml xylene cyanol). Reaction products were resolved on an 18% sequencing polyacrylamide gel containing 7M urea in Tris-Borate-EDTA buffer and visualized by autoradiography (Kodak X-OMAT film; Eastman Kodak, Rochester, NY).PAGE Analysis of RT Processive DNA Synthesis in the Presence of
Inhibitor.
Assay conditions were identical to that described
previously (Arion et al., 1996b
). Briefly, HIV-1 RT was
preincubated with 32P-labeled heteropolymeric T/P
at 37°C for 10 min. DNA synthesis was initiated by the simultaneous
addition of dNTPs plus the polymerization trap heparin (0.2 mg/ml).
Heparin competes with the binding of T/P for binding to free RT (Beard
and Wilson, 1993
). After appropriate incubation at 37°C in either the
absence or presence of varying concentrations of RT inhibitors,
reactions were quenched by addition of an equal volume of sequencing
gel loading buffer. Samples were heated for 5 min at 100°C and then
analyzed by denaturing PAGE using 16% polyacrylamide gels containing
7M urea. Products were visualized by autoradiography and quantified by densitometry.
Urea Denaturation of HIV-1 RT.
HIV-1 RT (200 nM) was
incubated with varying concentrations of urea (0-8M) in 50 mM
Tris-HCl, pH 7.5, and 50 mM sodium sulfate for 1 h. Changes in
protein structure and function were then assessed using a variety of
probes. The intrinsic tryptophan fluorescence of the enzyme was
monitored using a fluorescence excitation wavelength of 295 nm and
fluorescence emission wavelengths of 335 (in the absence of urea) and
352 nm (in the presence of 8M urea) using a T-format fluorescence
spectrometer. Data were plotted as a ratio of the fluorescence emission
values at 335 and 352 nm [i.e.,
F352(unfolded)/F335(folded)]. Size-exclusion high-performance liquid chromatography (HPLC) was carried out essentially as described previously (Sluis-Cremer et al.,
2000
). Circular dichroism experiments were carried out using a Jasco
J-750 spectrometer (Tokyo, Japan), and data are reported as mean
ellipticity values at 220 nm. For RT activity analyses, an aliquot of
the denatured RT was briefly assayed (4 min) to evaluate the residual
RT activity. Four-minute assays were used to ensure that no other
parameters (such as T/P) affected the equilibrium between heterodimer
and monomeric forms. Similar strategies have been successfully employed
previously (Divita et al., 1995).
Urea-Mediated Dissociation of the HIV-1 RT Heterodimer.
Urea
denaturation of p66/p51 HIV-1 RT, in the presence or absence of various
concentrations of N-acylhydrazones, was carried out
essentially as described previously (Sluis-Cremer et al., 2000b
).
Denaturation isotherms, obtained by following the loss of RT RDDP and
RNase H activities with increasing concentrations of denaturant, can be
approximated by a two-state transition between dimer and monomer
(Divita et al., 1994
). Denaturation curves were evaluated according to
a linear extrapolation method (Pace, 1986
). Briefly, an equilibrium
constant, Kd, was calculated at each
point in the transition region of the denaturation isotherm according to the following expression (Bowie and Sauer, 1989
; Timm and Neet, 1992
): Kd = Pt
fM2/(1
fM), where
Pt is the total protein concentration
of RT and fM is the fraction of
monomeric protein. fM was calculated
from the urea dissociation isotherms using the algorithm:
fM = (y100
y)/y100), where
y100 and y correspond to RT
activity in the absence (i.e., 100% active RT) and presence of varying
concentrations of urea, respectively. A linear dependence of the Gibbs
free energy of monomer formation (
G =
RT ln
Kd) on the denaturation concentration is assumed (Schellman, 1978
):
GD =
GDH2O
m[urea], where
GDH2O represents
the difference in Gibbs free energy between the monomer and dimer
transition in the absence of denaturant.
-Plot 5.0 (SPSS Science, Chicago,
IL) and a Levenberg-Marquardt least-squares algorithm.
| |
Results |
|---|
|
|
|---|
Urea Denaturation of the HIV-1 RT Heterodimer.
Urea is a
relatively strong denaturant, which at high concentrations favors the
complete unfolding of polypeptide chains. To optimize the concentration
of urea required to dissociate the RT subunits (but not promote
significant unfolding of the polypeptide chains), we evaluated the
changes in various structural and functional parameters of RT as a
function of urea concentration (Fig. 2). In light of the structural complexity of the enzyme, a variety of
probes were used to monitor changes occurring at different structural
levels during the denaturation process. These included size-exclusion
HPLC, tryptophan fluorescence (the 37 tryptophan residues in RT provide
a "fingerprint" for tertiary structure), far-ultraviolet circular
dichroism (CD; probe for protein secondary structure), and RT activity
itself. The denaturation isotherms for each of these probes are
illustrated in Fig. 2. The isotherms monitored by size-exclusion HPLC
and RT activity are coincident, suggesting that loss of RT activity is
a direct result of dissociation of the heterodimer and not a result of
conformational change preceding dissociation. Analyses of the
denaturation isotherms monitored by CD spectroscopy indicate that no
significant changes in protein secondary are observed during the
dimer-monomer transition. However, a small increase in the ratio of the
tryptophan fluorescence emission at 335 and 352 nm is observed. This
increase may result from the exposure of tryptophan residues that are
buried in the RT dimer interface (five in the p66 subunit and two in
the p51 subunit), as has been suggested previously (Divita et al.,
1993
). It was previously reported that the dissociation of RT subunits
was accompanied by significant changes (increased fluorescence and
large spectral shifts) in tryptophan fluorescence (Divita et al.,
1993
). However, in the present study, only small changes in
fluorescence intensity and emission maximum wavelength were noted
compared with that noted upon complete unfolding of the subunits (Fig.
2, inset). Our experiments suggest that the addition of a relatively
low concentration of urea promotes dissociation of the subunits, and that this dissociation phenomenon can be monitored accurately by
evaluating the loss of RT activity. Furthermore, it implies that no
significant structural changes (or unfolding events) are associated
with dissociation of the RT heterodimer subunits.
|
Urea Dissociation of HIV-1 RT Heterodimer in the Absence and
Presence of BBNH.
Because RT activity is dependent on the
quaternary structure of the enzyme, we used this parameter to evaluate
the effect of BBNH binding on the intrinsic stability of the HIV-1 RT
dimer. Figure 3 illustrates dissociation
isotherms of heterodimeric p66/p51 RT. In the absence of inhibitor, the
transition from RT dimer to monomer can be described by a sharp
sigmoidal isotherm with a midpoint of denaturation
([urea]1/2) at 2.30M urea. The Gibbs free
energy of dimer dissociation in the absence of urea
(
GDH2O) is
estimated to be 10.1 kcal mol
1 for this
transition, and the m-value (linear dependence of
GD on urea concentration) is 3.6 kcal
mol
1 M
1. If HIV-1 RT is
preincubated (20 min) with BBNH and then subjected to urea
denaturation, the [urea]1/2 value is shifted to
lower urea concentrations. Values of 2.20, 1.85, and 1.76M were
calculated for RT denaturation isotherms in the presence of 2, 10, and
25 µM of BBNH, respectively. Furthermore, the
GDH2O and
m-value are decreased to 6.3 kcal
mol
1 and 2.3 kcal mol
1
M
1 in the presence of 25 µM BBNH,
respectively. The change in m-value in the presence of BBNH
may reflect differences in the solvent exposure of RT hydrophobic
residues in the dimeric and monomeric states and/or alterations in the
pathway by which the subunits dissociate due to ligand-induced changes
in the subunit interactions (Sluis-Cremer et al., 2000
).
|
Synthesis of BBNH Analogs and Characterization of Their
RT-Inhibitory Properties.
Previous biochemical data have suggested
that BBNH binds to both the DNA polymerase and RNase H domains of HIV-1
RT (Borkow et al., 1997
; Arion et al., 2002
). To determine whether
multisite binding is an important criterion for
N-acylhydrazone-induced RT dimer destabilization, we used
new BBNH analogs that were found to selectively inhibit either RT DNA
polymerase or RNase H activity (Table 1),
namely BBSH (Fig. 1, compound 2), which inhibits RT RDDP activity with
a similar potency to BBNH but does not inhibit RT RNase H activity, and
DABNH (Fig. 1, compound 3), which inhibits RT RNase H activity with a
similar potency to BBNH (~4 µM) but is virtually inactive against
RT RDDP activity (IC50
20 µM). Furthermore,
we evaluated the ability of BBNH and BBSH to inhibit RT-containing
mutations associated with resistance to nonnucleoside reverse
transcriptase inhibitors (NNRTIs). NNRTI-resistant RT (including K103N,
Y181C, Y188H, and E138K) remained sensitive to inhibition by BBNH and
BBSH (data not shown), consistent with previously published data
(Borkow et al., 1997
).
|
|
Effect of BBNH Analogs on the Stability of RT Heterodimer Subunit
Interactions.
The curves for urea-induced dissociation of p66/p51
HIV-1 RT in the presence of varying concentrations of the
N-acylhydrazones used in the present study showed that only
BBNH and BBSH significantly destabilize the enzyme dimer in a
concentration-dependent manner (Fig. 5;
Table 2). The maximum change in
GDH2O
(
G) for p66/p51 HIV-1 RT is 3.80 kcal
mol
1 and 3.72 kcal mol
1
in the presence of BBNH and BBSH, respectively (Table 2). This observed
decrease in
GDH2O
falls within the theoretical limit by which small-molecule ligand binding can contribute to the destabilization of macromolecular conformation (Freire, 1998
). In contrast, the dissociation isotherms for the HIV-1 RT complex with DABNH are virtually identical to those
obtained in the absence of inhibitor. It therefore seems that inhibitor
binding to the DNA polymerase domain, but not to the RNase H domain,
results in the observed destabilization of the RT dimer by
N-acylhydrazones.
|
|
Effect of Inhibitor Concentration on RT DNA Polymerase Activity
under Processive Conditions.
NNRTIs, such as nevirapine, block
RT-catalyzed DNA synthesis in regions of the RNA or DNA template that
are rich in secondary nucleic acid structure (Arion et al., 1996b
;
Götte et al., 1999
). This results in RT exhibiting a mode of DNA
polymerization that is more distributive in the presence of certain
NNRTIs under single processive-cycle conditions (Kopp et al., 1991
;
Olsen et al., 1994
; Arion et al., 1996b
). We have previously
shown significant differences in the processivity of DNA synthesis
carried out by HIV-1 RT in the presence of nevirapine and
TSAOe3T (Arion et al., 1996b
). Because BBNH and
BBSH destabilize RT subunit interactions, as does
TSAOe3T (Sluis-Cremer et al., 2000b
), we examined
the effect of N-acylhydrazones on RT-processive DNA
polymerization to ascertain whether there may be any similarities
between these inhibitors and TSAOe3T.
)DNA (Arts et al., 1994
|
| |
Discussion |
|---|
|
|
|---|
To date, the majority of all compounds described that inhibit
HIV-1 RT target the DNA polymerase activity of the enzyme (Parniak and
Sluis-Cremer, 2000
). BBNH is unique in that it inhibits both the DNA
polymerase and RNase H activities of the enzyme (Borkow et al., 1997
).
We previously suggested that this multifunctional inhibition resulted
from the binding of two molecules of BBNH per molecule of HIV-1 RT at
two spatially separate sites. We proposed that one molecule bound close
to the nonnucleoside RT inhibitor binding pocket in the polymerase
domain of the enzyme, whereas the second molecule interacted with the
spatially distinct RNase H active site (Borkow et al., 1997
). Our
recent molecular modeling and mutagenesis studies further support this
hypothesis (Arion et al., 2002
). BBNH binding to the RNase H domain of
HIV-1 RT seems to require an aromatic stacking interaction between
Tyr-501 and the naphthyl ring of BBNH. Mutation of Tyr-501 to Arg
severely attenuates the ability of BBNH to inhibit the RNase H activity of HIV-1 RT. In contrast, the DNA polymerase activity of these mutant
enzymes remained as sensitive to inhibition of BBNH as the wild-type enzyme.
We now show that BBNH binding to HIV-1 RT impacts on the
protein-protein interactions of the heterodimeric enzyme by decreasing the Gibbs free energy of dimer destabilization by 3.8 kcal
mol
1. To evaluate whether this observed effect
was mediated by BBNH binding to one or both sites in RT, we synthesized
more than 100 analogs of BBNH and evaluated their ability to inhibit RT
RNase H and DNA polymerase activities. From these analogs, we
identified two compounds that specifically inhibited either the RT DNA
polymerase (BBSH) or RNase H (DABNH) activity of RT. As indicated
above, we recently demonstrated that the binding of hydrazone molecules in the RT RNase H domain involves an important
-
stacking
interaction between the phenol ring of Tyr-501 and the second ring of
the naphthyl moiety of BBNH. The observation that BBSH, a BBNH analog with a reduced ring system (Fig. 1), is unable to inhibit RT RNase H is
consistent with this model. At present, the structural features of
DABNH that give rise to its unique inhibitory properties are not
understood; however, crystallographic studies are in progress to
evaluate its binding interaction with RT. Nonetheless, the identification of these BBNH analogs has unequivocally demonstrated that N-acylhydrazone compounds can be developed that target
either activity, and furthermore, it has enabled us to identify that their binding to the RT DNA polymerase domain exerts the observed destabilization of heterodimeric HIV-1 RT. It should be noted that BBNH
and BBNH do not dissociate the RT heterodimer subunits; instead, their
binding seems to induce conformational changes that impact on the
protein-protein interactions of the enzyme and consequently affect the
DNA polymerase active site. We previously reported that
TSAOe3T, a highly modified nucleoside based
compound, inhibits RT DNA polymerase activity via an analogous
mechanism (Sluis-Cremer et al., 2000b
).
We previously showed that the binding of other NNRTIs, such as
nevirapine and UC781, to RT do not destabilize RT subunit interactions (Sluis-Cremer et al., 2000b
). Interestingly, Tachedjian et al. (2001)
recently reported that several NNRTIs (including
nevirapine and UC781) actually enhance the dimerization of HIV-1 RT.
The mechanism by which this observed enhancement arises remains
unclear. One hypothesis suggested that NNRTI binding stabilizes the RT heterodimer and thus shifts the dimerization binding equilibrium to
heterodimer formation (Tachedjian et al., 2001
). However, this hypothesis is not supported by the wealth of crystal structure data
currently available, and evaluation of the buried surface area in the
dimer interface of HIV-1 RT in the absence of inhibitors with that of
the enzyme complexed with various NNRTIs does not correlate with the
observed enhancement described by Tachedjian et al. (2001)
(Menéndez-Arias et al., 2001
). This is consistent with our
observations that NNRTI binding to purified dimeric HIV-1 RT does not
impact significantly on the dimeric structure of the enzyme
(Sluis-Cremer et al., 2000b
).
TSAOe3T also destabilizes RT subunit
interactions, and our modeling studies suggested that
TSAOe3T could bind to a site that is overlapping
with, but distinct from, the NNRTI binding site (Sluis-Cremer et al.,
2000b
). X-ray diffraction studies show that BBNH is a flat planar
molecule (Lanthier et al., 1997
), and preliminary modeling studies
suggest that it cannot be readily accommodated in the NNRTI binding
pocket. We propose that N-acylhydrazones may bind to RT at a
site close to, but distinct from, the NNRTI binding pocket in a manner
analogous to TSAOe3T, and that this difference in
binding relative to other NNRTIs may impact on RT subunit interaction
stability. This different mode of binding is consistent with the
differences in BBNH and TSAOe3T inhibition of RT
RNA-dependent DNA synthesis under processive conditions compared with
other NNRTIs, such as nevirapine. Neither TSAOe3T
(Arion et al., 1996b
) nor BBNH or BBSH promote dissociation and/or stalling of RT on a heteropolymeric RDDP template. The distribution of DNA synthesis products, including full-length product,
do not differ significantly from that noted with uninhibited enzyme
(except for the reduction in product levels). In contrast, nevirapine
prevents the similar conditions (Arion et al., 1996a
). On the other
hand, nevirapine prevents the formation of full-length DNA product
(p + 173), and there is a corresponding accumulation of
smaller polymerization products in regions of the RNA template [that
is, formation of full-length DNA product (p + 173) with a
corresponding accumulation of smaller polymerization products in
regions of the RNA template that are rich in secondary structure]. NNRTI binding alters the conformation of the "thumb domain" and displaces the orientation of the "primer grip" region in RT
(Kohlstaedt et al., 1992
; Ding et al., 1995a
,b
; Ren et al., 1995a
,b
).
These regions are essential for the correct positioning of the primer terminus in the active site and also for RT DNA polymerization processivity and translocation (Jacques et al., 1994
; Ghosh et al.,
1996
; Powell et al., 1997
; Wohrl et al., 1997
). Thus, the NNRTI-induced
changes in RT structure can provide a plausible explanation for the
increased enzyme dissociation and polymerization stalling during viral
DNA synthesis in the presence of nevirapine under processive
conditions. The exact molecular mechanism whereby N-acylhydrazones (and/or TSAOe3T) destabilize RT structure
and how this destabilization process affects RT DNA polymerization remain unclear. It is of interest to note that neither
TSAOe3T nor BBSH inhibit RT RNase H activity
despite the inhibitor-induced weakening of the RT subunit interactions.
This suggests that although the RT dimer form may be obligatory for the
activity of RNase H (Restle et al., 1990
, 1992
), small changes in the
stability of the subunit interactions of RT do not impact on this
activity, even though they provide considerable alterations of the DNA
synthetic capacity of the enzyme.
In summary, we have now identified two structurally diverse classes of
small organic molecules, TSAOe3T (Sluis-Cremer et
al., 2000b
) and certain N-acylhydrazones, that act as
"molecular crowbars" to destabilize the interactions of the RT
dimer subunits. These molecules illustrate that small organic compounds
can indeed impact on protein-protein interactions and may provide
useful leads in the search for additional such compounds for use as
antiviral agents.
| |
Footnotes |
|---|
Received September 28, 2001; Accepted April 29, 2002
This work was supported in part by grants from the Medical Research Council of Canada and the International Research Scholars Program of the Howard Hughes Medical Institute (to M.A.P.) and a postdoctoral fellowship from the Medical Research Council of Canada (to N.S.-C.).
This work was initiated while the authors were at the Lady Davis Institute for Medical Research and McGill University AIDS Center, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada.
Address correspondence to: Michael A. Parniak, Ph.D., University of Pittsburgh School of Medicine, Division of Infectious Diseases, S818D, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261. E-mail: parniakm{at}msx.dept-med.pitt.edu
| |
Abbreviations |
|---|
HIV, human immunodeficiency virus;
BBNH, N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde
hydrazone;
BBSH, (4-t-butylbenzoyl)-2-hydroxy-1-salicylyl hydrazone;
CD, circular dichroism;
DABNH, (4,N,N-dimethylamino
benzoyl)-2-hydroxy-1-naphthyl hydrazone;
HPLC, high-performance liquid
chromatography;
RDDP, RNA-dependent DNA polymerase;
RNase H, ribonuclease H;
RT, reverse transcriptase;
T/P, template-primer;
TSAOe3T, 1-{spiro[4-amino-2,2-dioxo-1,2-oxathiole-5,3'-[2',5'-bis-O-(tert-butyldimethylsilyl)-
-D-ribofuranosyl]]}-3-ethylthymine;
NNRTI, nonnucleoside reverse transcriptase inhibitor.
| |
References |
|---|
|
|
|---|
-APA R95845 at 2.8Å resolution.
Structure
3:
365-379[Medline].
-D-ribofuranosyl]]}-3-ethylthymine.
Biochemistry
39:
1427-1433[CrossRef][Medline].This article has been cited by other articles:
![]() |
J. Auwerx, F. Rodriguez-Barrios, F. Ceccherini-Silberstein, A. San-Felix, S. Velazquez, E. De Clercq, M.-J. Camarasa, C.-F. Perno, F. Gago, and J. Balzarini The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A Mol. Pharmacol., September 1, 2005; 68(3): 652 - 659. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wapling, K. L. Moore, S. Sonza, J. Mak, and G. Tachedjian Mutations That Abrogate Human Immunodeficiency Virus Type 1 Reverse Transcriptase Dimerization Affect Maturation of the Reverse Transcriptase Heterodimer J. Virol., August 15, 2005; 79(16): 10247 - 10257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Balzarini, J. Auwerx, F. Rodriguez-Barrios, A. Chedad, V. Farkas, F. Ceccherini-Silberstein, C. Garcia-Aparicio, S. Velazquez, E. De Clercq, C.-F. Perno, et al. The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors Mol. Pharmacol., July 1, 2005; 68(1): 49 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Hannoush, K.-L. Min, and M. J. Damha Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors Nucleic Acids Res., November 29, 2004; 32(21): 6164 - 6175. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Shaw-Reid, V. Munshi, P. Graham, A. Wolfe, M. Witmer, R. Danzeisen, D. B. Olsen, S. S. Carroll, M. Embrey, J. S. Wai, et al. Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid J. Biol. Chem., January 24, 2003; 278(5): 2777 - 2780. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||